Wedbush lowered the firm’s price target on Geron (GERN) to $6 from $7 and keeps an Outperform rating on the shares following quarterly results. Based on the firm’s discussion with management, Wedbush believes both a lack of awareness of Rytelo overall, and an apparent wariness of cytopenias associated with Rytelo treatment are key issues for uptake – the firm sees these issues as fixable with recent HCP education efforts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GERN:
- Scotiabank downgrades Geron to Sector Perform on Rytelo launch challenges
- Geron downgraded to Sector Perform from Outperform at Scotiabank
- Geron Corporation’s Q1 2025 Financial Highlights
- Geron Corporation’s Earnings Call: Mixed Sentiments and Strategic Moves
- Positive Growth Prospects for Geron Amid Strategic Expansion and Strong Financial Position